Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain
May 2, 2011 (Issue: 1363)
Previously approved by the FDA for treatment of depression, general anxiety disorder, diabetic peripheral
neuropathic pain and fibromyalgia, duloxetine (Cymbalta – Lilly) has now also been approved for
treatment of chronic musculoskeletal...more
1. Duloxetine (Cymbalta) for diabetic neuropathic pain. Med Lett Drugs Ther 2005; 47:67.
2. Duloxetine (Cymbalta) for fibromyalgia. Med Lett Drugs Ther 2008; 50:57.
3. V Skljarevski et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010; 11:1282.
4. V Skljarevski et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010; 35:e578.
5. V Skljarevski et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009; 16:1041.
6. AS Chappell et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011; 11:33.
7. AS Chappell et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009; 146:253.
8. GG Briggs et al. Use of duloxetine in pregnancy and lactation. Ann Pharmacother 2009; 43:1898.
9. Retail cost at drugstore.com. Accessed April 21, 2011.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
